Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252310 | 0.95 | NFKB1 (0.53) | KAT8NFKB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11065001 | 0.83 | KAT8 (0.57) | KAT8NFKB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8628648 | 0.83 | SMN1; SMN2 (0.46) | KAT8NFKB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3256061 | 0.82 | GABRP (0.45) | NFKB1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9168365 | 0.82 | KAT8 (0.56) | KAT8NFKB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3255349 | 0.79 | SMN1; SMN2 (0.43) | NFKB1NPC1RAB9ASMN1; SMN2NFKB2 | |
| SCHEMBL29172965 | 0.77 | KEAP1 (0.41) | KAT8SMN1; SMN2RARBPPARAALDH1A1 | |
| SCHEMBL28573526 | 0.76 | LMNA (0.42) | SMN1; SMN2ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL2852928 | 0.74 | CHRNB2 (0.40) | NFKB1NPC1RAB9ASMN1; SMN2NFKB2 | |
| SCHEMBL10898270 | 0.74 | KAT8 (0.70) | KAT8RARBPPARAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| EP-2184981-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KAT8 4092/4885NFKB1 3548/4885NPC1 1009/4885 |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY1R | KAT8 4092/4885NFKB1 3548/4885NPC1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.